Cover Image
市場調查報告書

鮑氏不動桿菌感染疾病:開發平台分析

Acinetobacter Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255983
出版日期 內容資訊 英文 130 Pages
訂單完成後即時交付
價格
Back to Top
鮑氏不動桿菌感染疾病:開發平台分析 Acinetobacter Infections - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 130 Pages
簡介

鮑氏不動桿菌是革蘭氏陰性桿菌。鮑氏不動桿菌感染疾病雖然是不太常見的疾病,但一發病一般則會影響液體內容物(呼吸道和腦脊髓液、腹水、尿道等)多的內臟器官。症狀有發燒(高體溫)、紅腫、發熱或疼痛的皮膚、創傷等。原因有免疫系衰弱,衛生狀態不佳,可能會無法接受最新的手術和治療。

本報告提供全球鮑氏不動桿菌感染疾病治療藥的開發趨勢調查,提供您開發中產品的各開發階段比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,這個部門的最新趨勢,主要企業的檢討等資訊。

簡介

  • 調查範圍

鮑氏不動桿菌感染疾病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

鮑氏不動桿菌感染疾病:企業開發中的治療藥

鮑氏不動桿菌感染疾病:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

鮑氏不動桿菌感染疾病:企業開發中的產品

鮑氏不動桿菌感染疾病的治療藥開發企業

  • Achaogen Inc.
  • Adenium Biotech ApS
  • AmpliPhi Biosciences Corporation
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • AvidBiotics Corp.
  • Emergent BioSolutions Inc.
  • Evaxion Biotech
  • F. Hoffmann-La Roche Ltd.
  • FAB Pharma
  • FOB Synthesis, Inc.
  • LegoChem Biosciences, Inc
  • Melinta Therapeutics, Inc
  • Microbiotix, Inc.
  • MicuRx Pharmaceuticals, Inc.
  • Nosopharm SAS
  • Novan, Inc.
  • Omnia Molecular Ltd.
  • Pfizer Inc.
  • Phylogica Limited
  • Sarepta Therapeutics, Inc.
  • Sealife PHARMA GMBH
  • 鹽野義製藥
  • Synthetic Biologics, Inc.
  • Techulon, Inc.
  • Tetraphase Pharmaceuticals Inc.
  • Trana Discovery, Inc.
  • Vaxdyn, S.L.

鮑氏不動桿菌感染疾病:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • A-3APO
  • AA-139
  • ACHN-975 Prodrug
  • Acinetobacter vaccine
  • Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections
  • Antisense Oligonucleotide for Acinetobacter baumannii Infections
  • Antisense Oligonucleotide for Acinetobacter Baumannii Infections
  • AR-401
  • AvR2-V10
  • Biologics for Acinetobacter Baumannii
  • Cephalosporin + Beta-Lactamase Inhibitor
  • EV-035
  • Fab-001
  • FSI-1671
  • FSI-1686
  • GN-4474
  • LCB-100200
  • MBX-1162
  • MDN-0057
  • Monoclonal Antibodies for Gram-Negative Bacterial Infections
  • MRX-V
  • NOSO-95179
  • NVN-1000
  • OM-011818
  • pneumonia vaccine
  • RX-05
  • RXP-873
  • S-649266
  • SLP-0905
  • Small Molecule for Acinetobacter baumannii Infections
  • Small Molecule for Gram-Negative Nosocomial Infections
  • Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections
  • Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections
  • Small Molecules for Acinetobacter Infections
  • Small Molecules for Multi-Drug Resistant Bacterial Infections
  • Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections
  • Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections
  • Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections
  • SYN-001
  • Synthetic Peptide for Gram-Negative Bacterial Infections
  • TP-6076
  • VXD-001
  • VXD-003

鮑氏不動桿菌感染疾病:最近的開發平台趨勢

鮑氏不動桿菌感染疾病:暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8540IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H2 2016, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.

Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 31 and 18 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 4 molecules, respectively for Acinetobacter Infections.

Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acinetobacter Infections Overview
  • Therapeutics Development
    • Pipeline Products for Acinetobacter Infections - Overview
    • Pipeline Products for Acinetobacter Infections - Comparative Analysis
  • Acinetobacter Infections - Therapeutics under Development by Companies
  • Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes
  • Acinetobacter Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acinetobacter Infections - Products under Development by Companies
  • Acinetobacter Infections - Products under Investigation by Universities/Institutes
  • Acinetobacter Infections - Companies Involved in Therapeutics Development
    • Achaogen Inc.
    • Adenium Biotech ApS
    • Aridis Pharmaceuticals LLC
    • AstraZeneca Plc
    • AvidBiotics Corp.
    • Cellceutix Corporation
    • Emergent BioSolutions Inc.
    • Entasis Therapeutics Inc
    • Evaxion Biotech ApS
    • F. Hoffmann-La Roche Ltd.
    • FOB Synthesis, Inc.
    • Hsiri Therapeutics, LLC
    • LegoChem Biosciences, Inc
    • Melinta Therapeutics, Inc
    • MicuRx Pharmaceuticals, Inc.
    • Nosopharm SAS
    • Novabiotics Limited
    • Omnia Molecular Ltd.
    • Peptilogics, Inc.
    • Pfizer Inc.
    • Sarepta Therapeutics, Inc.
    • Sealife PHARMA GMBH
    • Shionogi & Co., Ltd.
    • Techulon, Inc.
    • Tetraphase Pharmaceuticals Inc.
    • Varinel, Inc.
    • Vaxdyn, S.L.
    • Xellia Pharmaceuticals ApS
  • Acinetobacter Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-3APO - Drug Profile
    • AA-139 - Drug Profile
    • ACHN-975 Prodrug - Drug Profile
    • Acinetobacter vaccine - Drug Profile
    • Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile
    • Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile
    • AR-401 - Drug Profile
    • AvR2-V10 - Drug Profile
    • CA-824 - Drug Profile
    • ETX-2514 - Drug Profile
    • EV-035 - Drug Profile
    • Fab-001 - Drug Profile
    • FSI-1671 - Drug Profile
    • FSI-1686 - Drug Profile
    • GN-4474 - Drug Profile
    • HT-06 - Drug Profile
    • HT-07 - Drug Profile
    • HT-10 - Drug Profile
    • LCB-010200 - Drug Profile
    • LCB-100200 - Drug Profile
    • MDN-0057 - Drug Profile
    • Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile
    • MRX-V - Drug Profile
    • NOSO-95179 - Drug Profile
    • NP-432 - Drug Profile
    • OM-011818 - Drug Profile
    • Peptides for Infectious Diseases - Drug Profile
    • PMX-100 - Drug Profile
    • PMX-1091 - Drug Profile
    • PMX-1142 - Drug Profile
    • PMX-229 - Drug Profile
    • PMX-633 - Drug Profile
    • pneumonia vaccine - Drug Profile
    • RX-05 - Drug Profile
    • RXP-873 - Drug Profile
    • S-649266 - Drug Profile
    • SLP-0901 - Drug Profile
    • SLP-0905 - Drug Profile
    • Small Molecule for Acinetobacter baumannii Infections - Drug Profile
    • Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile
    • Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections - Drug Profile
    • Small Molecules for Acinetobacter baumannii Infection - Drug Profile
    • Small Molecules for Acinetobacter Infections - Drug Profile
    • Small Molecules for Bacterial Infections - Drug Profile
    • Small Molecules for Bacterial Infections - Drug Profile
    • Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile
    • Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile
    • Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile
    • Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile
    • SPR-741 - Drug Profile
    • Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile
    • TP-6076 - Drug Profile
    • VAR-10100 - Drug Profile
    • VXD-001 - Drug Profile
    • VXD-003 - Drug Profile
    • XEL-1001 - Drug Profile
    • XEL-1002 - Drug Profile
    • XEL-1003 - Drug Profile
    • XEL-1007 - Drug Profile
  • Acinetobacter Infections - Dormant Projects
  • Acinetobacter Infections - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acinetobacter Infections, H2 2016
  • Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Acinetobacter Infections - Pipeline by Achaogen Inc., H2 2016
  • Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H2 2016
  • Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Acinetobacter Infections - Pipeline by AstraZeneca Plc, H2 2016
  • Acinetobacter Infections - Pipeline by AvidBiotics Corp., H2 2016
  • Acinetobacter Infections - Pipeline by Cellceutix Corporation, H2 2016
  • Acinetobacter Infections - Pipeline by Emergent BioSolutions Inc., H2 2016
  • Acinetobacter Infections - Pipeline by Entasis Therapeutics Inc, H2 2016
  • Acinetobacter Infections - Pipeline by Evaxion Biotech ApS, H2 2016
  • Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Acinetobacter Infections - Pipeline by FOB Synthesis, Inc., H2 2016
  • Acinetobacter Infections - Pipeline by Hsiri Therapeutics, LLC, H2 2016
  • Acinetobacter Infections - Pipeline by LegoChem Biosciences, Inc, H2 2016
  • Acinetobacter Infections - Pipeline by Melinta Therapeutics, Inc, H2 2016
  • Acinetobacter Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2016
  • Acinetobacter Infections - Pipeline by Nosopharm SAS, H2 2016
  • Acinetobacter Infections - Pipeline by Novabiotics Limited, H2 2016
  • Acinetobacter Infections - Pipeline by Omnia Molecular Ltd., H2 2016
  • Acinetobacter Infections - Pipeline by Peptilogics, Inc., H2 2016
  • Acinetobacter Infections - Pipeline by Pfizer Inc., H2 2016
  • Acinetobacter Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2016
  • Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H2 2016
  • Acinetobacter Infections - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Acinetobacter Infections - Pipeline by Techulon, Inc., H2 2016
  • Acinetobacter Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016
  • Acinetobacter Infections - Pipeline by Varinel, Inc., H2 2016
  • Acinetobacter Infections - Pipeline by Vaxdyn, S.L., H2 2016
  • Acinetobacter Infections - Pipeline by Xellia Pharmaceuticals ApS, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acinetobacter Infections - Dormant Projects, H2 2016
  • Acinetobacter Infections - Dormant Projects (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Acinetobacter Infections, H2 2016
  • Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top